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Abstract
A meeting sponsored by the Bill & Melinda Gates Foundation was held at the Avanti Hotel, Mohammedia, Morocco,
July 14–15, 2015. The meeting resulted in the formation of the Cattle Tick Vaccine Consortium (CATVAC).
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Control of cattle tick infestations: an urgent need
in Africa
According to results from a continent-wide survey in
Africa conducted in 2014–2015, ticks and tick-transmitted
diseases, gastrointestinal helminth infections, and Peste
des Petits Ruminants (PPR) are the most important
diseases that affect the livelihood and development of
communities in rural Africa that depend on livestock [1].
Extensive use of acaricides to control tick infestation has
led to the selection for strains that are resistant against a
number of these drugs [2]. This is particularly evident for
the cattle tick Rhipicephalus microplus due to the fact that
the different tick stages develop on a single host. Recently,
it became apparent that this tick species is now spreading
over even larger areas of the African continent, thus
posing an immediate and further threat to livestock.
Additional control methods are urgently required to limit
tick populations [3].
Ever since it was shown that blood-feeding ectopara-
sites were affected when feeding on hosts that had been
vaccinated with crude extracts of these arthropods,
researchers aimed at developing effective vaccines [4, 5].
These efforts have met with some success in cattle tick
vaccine research, but none of the vaccines appeared
effective enough to sufficiently control tick infestation or
transmission of the pathogens carried by them [5].
Until now, there have been few attempts to study the
effects of combinations of the partially protective tick
antigens, which could potentially enhance vaccine
efficacy against tick infestations and pathogen infection
and transmission. In order to establish a closer collabor-
ation between research groups that work on tick vaccines,
a two-day meeting sponsored by the Bill & Melinda Gates
Foundation was held on July 14-15th, 2015 at the Avanti
Hotel in Mohammedia, Morocco. Key players in tick
vaccine research from the different continents were
invited to give an update on their research and to partici-
pate in the discussions. The purpose of the meeting was
to exchange scientific knowledge, update the tick vaccine
research, and select possible combinations of tick antigens
that hold promise as an effective tick vaccine against cattle
ticks, R. microplus. At the meeting it was also decided to
establish a formal collaboration among the groups to
facilitate exchange of antigens and evaluation of candidate
vaccine formulations in standardized experimental models.
This collaboration resulted in the formation of the Cattle
Tick Vaccine Consortium (CATVAC; Fig. 1).
Cattle tick vaccination studies
Bm86/Bm95
The only recombinant tick vaccines on the market contain
100 μg of the immunoprotective midgut antigen Bm86 of
R. microplus produced in Pichia pastoris and are formu-
lated in water-in-oil adjuvants. On average, the level of
protection obtained as judged by reduction of the number
of engorged females after tick infestation is approximately
50 %, but this percentage depends on the tick species and
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strain involved [6]. Moreover, post-engorgement female
mortality and effects on female fertility may reduce the
number of infective larvae by up to a maximum of 90 %,
depending on tick strains [6]. Additionally, Peter Willadsen
indicated that Bm86 produced in Escherichia coli and
baculovirus has also been successfully used as vaccine anti-
gens [7].
Full-length Bm86 antigen
In a comparative study performed in Texas, USA using
Gavac® and a third party-derived formulation with
Bm86, it was shown that efficacy against R. microplus
was 27 and 50–65 % depending on the tick strain and
adjuvant formulations used. However, vaccine efficacy
was close to 100 % against Rhipicephalus annulatus
strains [8]. These results corroborate the hypothesis that
strain differences affect the vaccine efficacy against R.
microplus that is observed in different models/experi-
ments [9]. It was emphasized by a number of presenters
that vaccination with Bm86 is generally more effective
against R. annulatus than against R. microplus [10]. In
addition, cattle vaccinated with Bm86 were significantly
protected against infestation with Rhipicephalus decolor-
atus, but not against Rhipicephalus appendiculatus [11].
Cattle vaccination with the Bm86 homologue of R.
appendiculatus affected moulting from nymphs to adults
from 95.5 to 89.3 %, a statistically significant effect [12].
The antigen (approximately 100 μg protein per vaccine
dose) was delivered subcutaneously as three separate
inoculations at four week intervals in Montanide ISA
50 V (Seppic). Duration of immunity studies revealed
that immunity induced with Bm86/Bm95 could last for
5–6 months, which has also been suggested after evalu-
ation of the performance of the commercial vaccines
TickGARD® and Gavac® over a period of 10 years in the
field [6]. A single yearly booster vaccination is required
to maintain this level of immunity. Gavac® is commer-
cially available in Latin American countries such as
Cuba and Venezuela. TickGARD® is not commercially
available anymore but Alicja Lew-Tabor (The University
of Queensland, Australia) mentioned that some stock is
still available from Queensland University.
Synthetic partial Bm86 antigen
Joaquín Patarroyo (Universidade Federal de Viçosa,
Brazil) presented results in which a vaccine based on
three peptides of the Bm86 protein that differ only at
two amino acid positions from the original Australian
tick sequence is being used in the field in Brazil with
2 mg of recombinant protein per dose with 1.5 mg of
saponin as adjuvant [13]. Cattle were vaccinated three
times with a 30-day interval. Protection against tick
infestation is >80 % reduction in engorged females.
This study, which includes a number of non-
vaccinated control farms where acaricide treatment is
used to control tick populations, is on its third year
and involves 15,000 cattle head in total.
Ferritin 2(Fer-2)
Fer-2 is a secreted molecule expressed in tick gut that
functions in inter-tissue transport of non-heme iron
originating from blood meal [14]. Vaccination of
rabbits with Fer-2 from Ixodes ricinus expressed in E. coli
provided protection against infestation with I. ricinus ticks
(43 % reduction in numbers of engorged female ticks;
[15]. The Fer-2 homologue of R. microplus adjuvanted
with Montanide ISA 50 V also induced protection when
used as a vaccine in one experiment using cattle and
R. microplus tick infestation. The protective effect was
reflected in the number of engorged females being
reduced by 30 % and an additional effect on fertility result-
ing in a total efficacy of 64 % on viable progeny [15]. Petr
Kopáček (Institute of Parasitology, Biology Centre Czech
Academy of Sciences, Czech Republic) presented a re-
peat study showing only partial protection affecting
mainly oviposition and larval hatching and additional
repeat studies are ongoing. Kopáček also emphasized
the vaccination potential of other molecules possibly
playing a role in tick heme and iron metabolic path-
ways of I. ricinus that were recently screened using
RNA-interference (RNAi) and experimental vaccin-
ation of rabbits. However, none of the tested mole-
cules surpassed Fer-2 in their impact on the tick
development and reproduction.
Fig. 1 The participants of the official launch meeting of CATVAC. G.A. Scoles not on the picture. This meeting was held in Mohammedia, Morocco,
July 14–15, 2015
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Subolesin (SUB)
SUB is an intracellular regulatory protein that is involved
in signal transduction. José de la Fuente (SaBio, Instituto
de Investigación en Recursos Cinegéticos, Spain) re-
ported that cattle vaccination with SUB from R. micro-
plus adjuvated with Montanide ISA 50 V reduced the
numbers of engorged female ticks after infestation with
R. microplus by 47 % (60 % total efficacy considering the
effect on oviposition and fertility; [5]). Similar results were
found on vaccinated white-tailed deer. Additionally,
partial protection has also been found for various hard
and soft tick species and for other ectoparasites such as
poultry red mite, mosquitoes and sand flies, hence its ap-
plicability in vaccines against haematophagous arthropods
appears relatively wide [5]. Additionally, the effect of SUB
vaccination on tick pathogen infection or transmission
has been also documented, therefore suggesting its
possible application to control vector infestations and
pathogen infection [5]. A chimeric protein (Q38) that
contains protective epitopes identified in SUB and the
mosquito orthologue Akirin was used to vaccinate cattle
(three intramuscular vaccinations; [16]). A single dose
consisted of 100 μg protein produced in E. coli and
formulated with Montanide ISA 50 V adjuvant. Upon
infestation with R. microplus, a reduction of 69 % in
the number of engorged females was observed. There
was some additional effect on oviposition with 75 %
total efficacy.
SILK antigen
de la Fuente reported that the R. microplus SILK antigen
was discovered for its role in tick-Anaplasma marginale
interactions and used to vaccinate cattle with 3 intra-
muscular vaccinations [16]. A single dose consisted of
100 μg protein produced in E. coli and formulated with
Montanide ISA 50 V adjuvant. Upon infestation with R.
microplus a reduction of 58 % in the number of
engorged females was observed. There was little add-
itional effect on oviposition with 62 % total efficacy.
New vaccine antigen candidates
A number of research groups are using reverse vaccinology
or vaccinomics to discover new vaccine antigen candidates
[5, 17]. In order to limit the number of putative vaccine
candidates, a number of selection criteria is being used
such as antigens that evoke antibodies that interfere with
coagulation or in vitro feeding of adult ticks. Some of these
candidates were presented that have been tested in
vaccination-challenge experiments. These new candidates
include (a) antigens interfering with blood coagulation and
digestion (TCX, reprolysins), (b) antigens interfering with
in vitro tick feeding (mix of 6 peptides), and (c) antigens
interfering with tick biology (Aquaporins). A Kunitz-type
protein with unknown function that is found on the cell
surface of R. microplus midgut cells (TCX), was identified
as one of three protein-binding partners of Bm86 using a
yeast two-hybrid assay [18]. Upon infestation with R.
microplus larvae, a reduction of 74 % in the number of
engorged adult female ticks was found with a significant
phenotype of “dandruff-like” nymphs and young adults. In
studies using a combination of TCX and Bm86, the
effect of Bm86 was increased four-fold. In addition, a
combination of reprolysins, a group of metalloproteases
from R. microplus [19] was used to vaccinate calves and
induced approximately 60 % reduction in the number of
engorged females. All antigens were produced in E.coli
and calves were vaccinated with 100 μg antigen subcuta-
neously as three separate inoculations at four week inter-
vals in Montanide ISA 50 V.
Lew-Tabor reported that a mix of 6 peptides that were
selected because of the fact that antibodies against
those peptides reduced the proportion of ticks that
successfully completed a blood meal in vitro was used
to vaccinate cattle [17]. Upon infestation with R.
microplus larvae, a reduction of >85 % in the number
of engorged adult female ticks was found. When each
of these peptides was evaluated individually, protection
was usually much less (15–45 %), but trials are on-going
testing the use of new formulations with these putative
protective antigens.
During feeding ticks concentrate the blood meal in the
midgut by removing water and excreting it back into the
host as saliva. Aquaporins are membrane proteins that
have been identified as playing a major role in this
process. Out of three aquaporin genes identified in R.
microplus, the potential use of Aquaporin 1 (RmAQP1)
as a vaccine was recently tested. In two independent pen
trials conducted in Brazil using Holstein calves vacci-
nated with Pichia-expressed recombinant RmAQP1
there was a high efficacy of 75 and 68 %, respectively,
mainly due to the clear reduction in number of adult
ticks that fed successfully [20]. The importance of
Aquaporin 2 (RmAQP2) was demonstrated by RNAi
mediated blocking of expression of this gene. There was
a significant reduction in tick reproductive fitness and
larval viability [21]. Interestingly, Glen A. Scoles (USDA,
Washington State University, USA) reported that this
effect appeared to be higher when the ticks were
infected with Babesia bovis.
Combined antigens
In order to increase the level of protection by vaccination
it has been suggested earlier to test combinations of anti-
gens that each had shown to induce partial protection
against tick infestations. A number of antigens have been
used in combination with the Bm86 midgut protein with
variable results. Theo Schetters (ProtActivity R&D, The
Netherlands) reported on the use of Bm86 combined with
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SUB. Cattle that were vaccinated with 100 μg of Bm86
produced in P. pastoris and 50 μg of SUB produced in E.
coli in separate vaccine formulations in Montanide ISA
50 V2 adjuvant were almost completely protected against
R. microplus infestation (>95 % reduction in the number
of engorged females; [22]). In vitro feeding studies using
R. microplus larvae suggested that the effect is due to the
synergistic activity of antibodies against each of the
antigens. De la Fuente presented results using a chimeric
protein composed of antigenic peptides from the Bm95
protein and the complete SUB protein fused to the A.
marginale MSP1a protein to present the antigens on the
surface of recombinant E. coli [23]. The bacterial mem-
brane fraction containing 120 μg of recombinant chimeric
protein per dose adjuvanted with Montanide ISA50V2
was given three times through the intramuscular route
and induced 60 % reduction in R. microplus infestations
and 91 % efficacy considering the reduction of viable
progeny in a preliminary trial in cattle.
Efficacy models
In order to evaluate the protective effects of cattle
vaccination with tick antigens, a number of efficacy
models are being used. Especially when using reverse
vaccinology or vaccinomics, there is a need for efficient
screening systems to select putative vaccine antigen can-
didates [5, 17]. Results obtained with different models
were presented, and pros and cons were discussed.
In vitro models
Blocking of gene expression using RNAi can be used to
discover genes that are essential for tick biology, how-
ever, this strategy does not specifically select for vaccine
antigen candidates. Because protective immunity against
tick infestation is mainly antibody mediated, a system
that shows the protective activity of serum from experi-
mental animals that were vaccinated with tick vaccine
formulations is needed. Preferably, antibodies should be
raised in immunized cattle but smaller laboratory animals
can also be used during this phase of antigen screening.
Protective activity of serum raised against Bm86 was
demonstrated using tube feeding of adult R. microplus
adult ticks and membrane feeding of R. microplus larvae
[22]. The latter system is expected to become publically
available this year, and has the advantage over capillary
tube feeding of semi-engorged adult females that it allows
more efficient screening of vaccine candidate antigens.
The application of this system for nymphs and adult ticks
needs to be validated. Importantly, in vitro feeding sys-
tems allow combining sera with different antigen specifi-
city to discover synergetic effects of antibodies raised
against these individual antigens. This combination in-
creases the efficiency of antigen screening, and reduces
the use of experimental animals and development costs. It
should be realized, however, that identification of effective
combinations of protective antigens by these methods
does not cover the entire spectrum of putative protective
antigens as some antigens will be missed.
In vivo models
Infestation of natural hosts with tick larvae is considered
the best model to study the effects of vaccination on tick
populations in the field. It was agreed at the meeting
that vaccine efficacy should be expressed as reduction in
the number of fully engorged adult ticks. There are
essentially two techniques used: infestation at a confined
space and whole body tick challenges. Confined tick
infestations have been used for several tick species such
as R. appendiculatus and I. ricinus using ear-wraps.
However, as presented by Juan Mosqueda (Universidad
Autónoma de Queretaro, Queretaro, Mexico), when
studying ticks from the Boophilus group, nettings that
are glued to the flank of the calf are usually applied, thus
creating a patch where ticks feed. Confined infestations
allow studying the effect of vaccination on different tick
species on a single animal. This method has been used
to study the effect of vaccination with Bm86 and SUB
against R. microplus and R. annulatus [22]. It was generally
agreed that whole body infestations reflect better a natural
field infestation of cattle. For whole body infestations,
larvae derived from tick colonies that are kept at the
laboratory are put on the bovines at one or, preferably,
more occasions at close intervals. In all cases, animals are
restrained from grooming (e.g., with a short halter) for the
duration of tick feeding to minimize grooming. Because
ticks of the Boophilus group are one-host ticks, larvae will
develop to nymphs and subsequently adults on the same
animal. Fully engorged ticks that drop off from the animals
in the third week after larval infestation must be recovered
from the tray below the grid floor and purified from con-
taminating feces. Ticks can also be incubated to determine
egg viability through the determination of percent emer-
ging larvae. It should be clear that whole body tick infesta-
tions do not easily allow studying the effect of vaccination
on different tick species, unless tick species determination
using molecular biological techniques is additionally per-
formed on ticks that are recovered from cattle. Schetters
emphasized that when using whole body infestation, a
minimal number of five cattle per experimental group is
required to detect relevant statistical differences of at least
60 % reduction in the number of engorged female ticks.
Ultimately, field experiments are required to study the
effect of vaccination on tick infestation. The major problem
is that the natural level of infestation cannot be controlled,
which increases the number of animals per experimental
group including a control group to reach a sufficient statis-
tical power. It is important to evaluate the different meth-
odologies used in field studies and standardize these in
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order to make comparison between different field trials.
There was some debate on whether a confined challenge
that forces the ticks to feed on a part of the body that is not
the preferred site for feeding, might not reflect the natural
situation. It was argued that the fact that in the natural
situation there are usually fewer ticks feeding on the flank
than for instance on the neck of the animals is likely due to
the fact that cattle groom themselves, and remove ticks
from those areas. An experimental trial that compares the
development of graded numbers of ticks applied at a patch
or applied as a whole body infestation was suggested.
An important parameter is the proportion of larvae
that develops to fully engorged ticks. The consortium
should agree upon a minimal value to consider a vaccine
formulation as efficacious for the control of cattle tick
infestations.
The way forward
The meeting participants agreed on the pipeline for the de-
velopment of effective vaccines for the control of cattle tick
infestations (Fig. 2) and expressed their desire to continue
this cattle tick vaccine initiative. It was suggested to
formalize the formation of a Cattle Tick Vaccine Consor-
tium (CATVAC). The consortium will be guided by a
Steering Committee formed by Christine Maritz-Olivier,
José de la Fuente and Theo Schetters (Chair) who will drive
the project and take responsibility to realize the action
points listed below.
Standardization of tick vaccine research
Standardization of tick vaccine research is of ultimate
importance to allow comparison of results obtained by
different research groups. A number of specific standards
were defined and included (a) positive antigen control, (b)
challenge model, (c) calculation of efficacy, and (d) correl-
ate of protection. The meeting agreed to establish a
positive antigen control for vaccine efficacy studies based
on Bm86. This control preparation will be used in future
efficacy trials. In addition, a standardized antibody test to
determine the antibody titres against Bm86 will be devel-
oped and shared among participants. The meeting also
agreed to define specific parameters for in vivo challenge
models. Parameters that can be standardized are the age
of the experimental animals, sex, breed, tick strain/colony
and number of larvae used for infestation, the minimal
proportion of larvae that develop to fully engorged adults,
and the challenge model (whole body or patch infest-
ation). In order to improve clarity about efficacy of tick
vaccines, especially the way this is communicated in
abstracts of scientific publications that are published on
line, it was decided to always present the percentage
reduction in the number of engorged females upon infest-
ation with R. microplus larvae. In the case that also the
effect of vaccination on oviposition and/or larval viability
has been determined, this will be expressed as total
efficacy, clearly stating which parameters were used to
calculate this value (see Box 2 in [5]). Research should aim
Fig. 2 Working pipeline proposed by CATVAC for development of effective vaccines for cattle tick control
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at defining a correlate of protection, which is a require-
ment for registration of the vaccine. Preferably, the correl-
ate of protection is the antigen content or the antibody
titer against the vaccine antigen(s). Such correlate of
protection will be used to establish a potency test for the
release of vaccine batches after quality control.
Guidelines for tick vaccine development
The standardization of tick vaccine research as described
above forms the basis for the formulation of guidelines
for tick vaccine development. These guidelines will be dis-
cussed with representatives of the World Association for
the Advancement of Veterinary Parasitology (WAAVP)
and submitted for publication in Veterinary Parasitology,
the official organ of the WAAVP.
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